{"altmetric_id":10400505,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Ascendis Pharma A\/S"],"first_seen_on":"2016-08-11T12:11:15+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1506521563,"links":["http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02781727","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02781727","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02781727?term=ascendis&rank=3"],"nct_id":"NCT02781727","pubdate":"2016-05-19T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)","type":"clinical_trial_study_record"},"altmetric_score":{"score":59,"score_history":{"1y":7,"6m":7,"3m":7,"1m":7,"1w":7,"6d":7,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":59},"context_for_score":{"all":{"total_number_of_other_articles":8462170,"mean":7.1084920520889,"rank":161422,"this_scored_higher_than_pct":98,"this_scored_higher_than":8300712,"rank_type":"exact","sample_size":8462170,"percentile":98},"similar_age_3m":{"total_number_of_other_articles":260189,"mean":12.00919810291,"rank":9975,"this_scored_higher_than_pct":96,"this_scored_higher_than":250205,"rank_type":"exact","sample_size":260189,"percentile":96},"this_journal":{"total_number_of_other_articles":24884,"mean":10.5455532693,"rank":600,"this_scored_higher_than_pct":97,"this_scored_higher_than":24282,"rank_type":"exact","sample_size":24884,"percentile":97},"similar_age_this_journal_3m":{"total_number_of_other_articles":1019,"mean":9.9735717092338,"rank":35,"this_scored_higher_than_pct":96,"this_scored_higher_than":984,"rank_type":"exact","sample_size":1019,"percentile":96}}},"demographics":[],"counts":{"total":{"posts_count":11},"news":{"unique_users_count":8,"unique_users":["ticker_tech","nasdaq","minyanville_finance","pr_newswire_uk","noodls","seeking_alpha","bioportfolio","yahoo_finance_singapore"],"posts_count":11}},"posts":{"news":[{"title":"Ascendis Pharma A\/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency","url":"http:\/\/ct.moreover.com\/?a=27578670489&p=1pl&v=1&x=WB7E3oX419bk5KS1ZfkpYA","license":"public","citation_ids":[10400505],"posted_on":"2016-08-11T12:03:43+00:00","summary":"COPENHAGEN, Denmark, Aug. 11, 2016 \/PRNewswire\/ -- Ascendis Pharma A\/S (Nasdaq: ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced the\u2026","author":{"name":"Ticker Tech","url":"http:\/\/www.tickertech.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/724\/normal\/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}},{"title":"Ascendis Pharma A\/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency","url":"http:\/\/ct.moreover.com\/?a=27578673865&p=1pl&v=1&x=gyGUMFvwi49ObpCSnxmzGw","license":"public","citation_ids":[10400505],"posted_on":"2016-08-11T12:00:00+00:00","summary":"COPENHAGEN, Denmark, Aug. 11, 2016 \/PRNewswire\/ -- Ascendis Pharma A\/S (Nasdaq:ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced the\u2026","author":{"name":"NASDAQ","url":"http:\/\/www.nasdaq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/839\/normal\/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}},{"title":"Ascendis Pharma A\/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency","url":"http:\/\/ct.moreover.com\/?a=27578688682&p=1pl&v=1&x=93mq66-IKd_x3selxLUG7g","license":"public","citation_ids":[10400505],"posted_on":"2016-08-11T12:00:00+00:00","summary":"COPENHAGEN, Denmark, Aug. 11, 2016 \/PRNewswire\/ -- Ascendis Pharma A\/S ( Nasdaq: ASND ), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced the\u2026","author":{"name":"Minyanville: Finance ","url":"http:\/\/finance.minyanville.com\/minyanville","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/637\/normal\/Screen_Shot_2016-02-02_at_16.44.51.png?1454431502"}},{"title":"Ascendis Pharma A\/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency","url":"http:\/\/ct.moreover.com\/?a=27578889546&p=1pl&v=1&x=dP5T-XstyGkqtCTyqT6JOg","license":"public","citation_ids":[10400505],"posted_on":"2016-08-11T12:00:00+00:00","summary":"- Following successful regulatory discussions, global heiGHt Trial to evaluate the only long-acting native, unmodified growth hormone in development - COPENHAGEN, Denmark, Aug.","author":{"name":"PR Newswire UK","url":"http:\/\/www.prnewswire.co.uk\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/894\/normal\/Screen_Shot_2016-01-27_at_14.12.41.png?1453903996"}},{"title":"Ascendis Pharma A\/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency","url":"http:\/\/ct.moreover.com\/?a=27579063865&p=1pl&v=1&x=stu_ooxvJikzSccZrZtEdQ","license":"public","citation_ids":[10400505],"posted_on":"2016-08-11T12:46:03+00:00","summary":"Ascendis Pharma A\/S (via noodls) \/ COPENHAGEN, Denmark, Aug. 11, 2016 \/PRNewswire\/ -- Ascendis Pharma A\/S (Nasdaq: ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical\u2026","author":{"name":"Noodls","url":"http:\/\/www.noodls.com\/index.asp","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/955\/normal\/Screen_Shot_2016-02-11_at_11.48.48.png?1455191394"}},{"title":"Ascendis Pharma commences late-stage study supporting lead product candidate","url":"http:\/\/ct.moreover.com\/?a=27579363586&p=1pl&v=1&x=AwKVrBvqmwSpsK9RzNLFYA","license":"public","citation_ids":[10400505],"posted_on":"2016-08-11T13:12:00+00:00","summary":"Ascendis Pharma A\/S (NASDAQ: ASND ) initiates a Phase 3 clinical trial, called heiGHt, evaluating lead product candidate TransCon Growth Hormone for the treatment of children with growth hormone deficiency (GHD).","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"Ascendis Pharma A\/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency","url":"http:\/\/ct.moreover.com\/?a=27579842960&p=1pl&v=1&x=ohpLd2oUZLrgTHF1s0NFlw","license":"public","citation_ids":[10400505],"posted_on":"2016-08-11T08:15:18+00:00","summary":"COPENHAGEN, Denmark, Aug. 11, 2016 \/PRNewswire\/ -- Ascendis Pharma A\/S (Nasdaq: ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced the\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"Ascendis Pharma A\/S Announces R&D Update to Review Expanded Pipeline and Long-term Strategic Outlook","url":"http:\/\/ct.moreover.com\/?a=27623866077&p=1pl&v=1&x=rq_aK6CR06MA9oqD3sE0Xg","license":"public","citation_ids":[10400505],"posted_on":"2016-08-15T20:08:00+00:00","summary":"COPENHAGEN, Denmark, Aug. 15, 2016 \/PRNewswire\/ -- Ascendis Pharma A\/S ( ASND ), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that the company\u2026","author":{"name":"Yahoo! Finance Singapore","url":"http:\/\/sg.finance.yahoo.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/721\/normal\/Screen_Shot_2016-01-26_at_15.33.41.png?1453822448"}},{"title":"Versartis VRS-317 stumble propels Ascendis; shares ahead 45% premarket","url":"http:\/\/ct.moreover.com\/?a=31920767977&p=1pl&v=1&x=YjB2S1xuxfxXs_ME-2qqpA","license":"public","citation_ids":[10400505],"posted_on":"2017-09-22T13:25:08+00:00","summary":"Thinly traded Ascendis Pharma A\/S (NASDAQ:ASND) is up 45% premarket on increased volume in response to Versartis' (NASDAQ:VSAR) failed Phase 3 clinical trial of VRS-317 in pediatric growth hormone deficiency.","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"Your Daily Pharma Scoop: Gilead At Mid-$80s, Keytruda's New Label, Ascendis's Positive Trial","url":"http:\/\/ct.moreover.com\/?a=31950423530&p=1pl&v=1&x=1FbP4FxjKlFug2q9XxaaLw","license":"public","citation_ids":[10400505,4683880,15730652],"posted_on":"2017-09-25T15:54:26+00:00","summary":"Summary We discuss a Gilead article. Is GILD a buy now? Keytruda gets a new label.","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"Your Daily Pharma Scoop: Nektar's Potential, Axovant Finally Fails, PTCT AdComm Tomorrow","url":"http:\/\/ct.moreover.com\/?a=31972690407&p=1pl&v=1&x=LkaGYq1hnD0IRU6vDv6Tdg","license":"public","citation_ids":[26652897,10400505],"posted_on":"2017-09-27T14:12:43+00:00","summary":"Sep.27.17 | About: Nektar Therapeutics (NKTR) Long\/short equity, newsletter provider, healthcare, biotech The Total Pharma Tracker Summary Nektar\u2019s strategy shifting and potential is discussed.","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}}]}}